The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled,
multicenter, open-label basket trial that aims to compare various antiviral treatments for
COVID-19. Moreover three substudies have been integrated. Currently, patients will be
randomized to receive (hydroxy-)chloroquine (Treatment stopped after reports of safety
issues), lopinavir/ritonavir, remdesivir or standard of care. Moreover, these patients are
eligible for substudy A (randomized to rivaroxaban 5mg 1-0-1 vs. standard of care), substudy
B (renin-angiotensin (RAS) blockade vs. no RAS blockade for patients with blood pressure
>120/80mmHg), and substudy C (asunercept vs standard of care, pentglobin vs. standard of care
for patients with respiratory deterioration and high inflammatory biomarkers).
Endpoints were chosen based on the master protocol published by the World Health Organisation
and include a 7-point scale of clinical performance, mortality, oxygen requirement (both dose
and type), duration of hospitalization, viral load and safety.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medical University of Vienna
Collaborators:
Hospital Hietzing Kaiser Franz Josef Hospital Kepler University Hospital Medical University Innsbruck Medical University of Graz Otto Wagner Hospital SMZ-Ost Donauspital Wilhelminenspital Vienna